Fig. 7

Potential therapeutic role of LINC02273 in breast cancer. a Schematic view of ASO targets on LINC02273 mRNA. b Relative expression of LINC02273 48 h after ASO transfection were determined by RT-qPCR (normalized to GAPDH). n = 3, biological replicates. c Immunoblotting analysis of AGR2 expression after ASO transfection in MDA-MB-231 cells. GAPDH were served as loading control. n = 3 independent experiments. d RT-qPCR showed LINC02273 expression after ASO delivery without transfect reagents. ASO were added into LM2 wild type cells at the concentration as indicated. After 48 h, RNA was extracted, and RT-qPCR was performed. Normalized to GAPDH, n = 3, biological replicates. e Schematic view of ASO treatment xenograft model. LM2 WT cells were injected into mammary fat pad. Mice were randomized into 3 groups 14 days later. ASO were diluted in PBS and delivered through tail vein twice a week with the concentration of 10 nmol foreach mouse. ASO NC targeted no known sequence with the same length of ASO-1 and ASO-2 were used as negative control. Tumor sizes were measured during treatment. Mice were sacrificed on the day 45. BLI was performed ex vivo. f Tumor volumes were measured in the NC and ASO groups in the xenograft mouse model (n = 8, independent t-test). g Representative images of BLI of lungs and statistical analysis of photon flux. Scale bar: 4 mm. Statistical analysis of total photon flux is on the right (n = 8, Mann-Whitney test). h LINC02273 and AGR2 expression in xenograft tumor were determined by RT-qPCR (n = 8, Mann-Whitney test). i Schematic diagram of hnRNPL-LINC02273-AGR2 axis regulating breast cancer metastasis. For (b), (d), and (f-g), means ± s.e.m. are shown. For (b) and (d), P values were determined by independent sample t-tests. *P < 0.05, **P < 0.01, ***P < 0.001